| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Cell Biology and Immunology, Berlex Biosciences, Inc., Alameda, California 94501
A monoclonal antibody (TAb 250) specific to an extracellular epitope of the c-erbB-2 protein (gp185) inhibited the in vitro proliferation of human breast tumor cell lines that overexpress c-erbB-2 in a dose-dependent manner. Treatment of cells with combinations of cis-diammedichloroplatinum (CDDP) and TAb 250 resulted in a significantly enhanced cytotoxic effect. This synergistic cytotoxicity was apparent over a wide range of antibody concentrations (200 pg/ml-100 µg/ml) including concentrations that showed no inhibitory effect alone. TAb 250 did not increase the cytotoxic effect of CDDP in a cell line exhibiting no detectable level of gp185. Athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of gp185 showed a greatly enhanced inhibition of tumor growth when treated with TAb 250 and CDDP compared to treatment with the antibody or CDDP alone. This effect was specific inasmuch as TAb 250 did not enhance the growth-inhibitory effect of CDDP on tumor xenografts which were not expressing gp185.
1 Present address: Somatix Therapy, Inc., 850 Marina Village Parkway, Alameda, CA 94501.
2 To whom requests for reprints should be addressed.
Received 2/28/91. Accepted 6/20/91.
This article has been cited by other articles:
|
|
 |
|
  S. Paik, Y. Taniyama, and C. E. Geyer Jr Anthracyclines in the Treatment of HER2-Negative Breast Cancer J Natl Cancer Inst, January 2, 2008; 100(1): 2 - 4. [Full Text] [PDF]
|
|
|
|
 |
|
 R. STEFANO, B. AGOSTARA, M. CALABRỎ, I. CAMPISI, B. RAVAZZOLO, A. TRAINA, M. MIELE, and L. CASTAGNETTA Expression Levels and Clinical-Pathological Correlations of HER2/neu in Primary and Metastatic Human Breast Cancer Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 463 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. X. Xing, X. F. Hu, G. A. Pietersz, H. L. Hosick, and I. F. C. McKenzie Cripto: A Novel Target for Antibody-Based Cancer Immunotherapy Cancer Res., June 1, 2004; 64(11): 4018 - 4023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Pegram, G. E. Konecny, C. O'Callaghan, M. Beryt, R. Pietras, and D. J. Slamon Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 739 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Pegram, T. Pienkowski, D. W. Northfelt, W. Eiermann, R. Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, et al. Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer J Natl Cancer Inst, May 19, 2004; 96(10): 759 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.L. Tedesco, A.D. Thor, D.H. Johnson, Y. Shyr, K.A. Blum, L.J. Goldstein, W.J. Gradishar, B.P. Nicholson, D.E. Merkel, D. Murrey, et al. Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization-Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial J. Clin. Oncol., March 15, 2004; 22(6): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Bookman, K. M. Darcy, D. Clarke-Pearson, R. A. Boothby, and I. R. Horowitz Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group J. Clin. Oncol., January 15, 2003; 21(2): 283 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Drake and J. L. Becker Aspirin-Induced Inhibition of Ovarian Tumor Cell Growth Obstet. Gynecol., October 1, 2002; 100(4): 677 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ohta, Y. Tokuda, Y. Suzuki, M. Kubota, T. Watanabe, H. Fujii, Y. Sasaki, T. Niwa, H. Makuuchi, and T. Tajima A Case with HER2-overexpressing Breast Cancer Completely Responded to Humanized anti-HER2 Monoclonal Antibody Jpn. J. Clin. Oncol., November 1, 2001; 31(11): 553 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bergman, M. A. Barmada, J. A. Griffin, and D. J. Slamon Treatment of Meningeal Breast Cancer Xenografts in the Rat Using an Anti-P185/HER2 Antibody Clin. Cancer Res., July 1, 2001; 7(7): 2050 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamauchi, V. Stearns, and D. F. Hayes When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2334 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Summerhayes Trastuzumab in the treatment of HER2 positive breast cancer Journal of Oncology Pharmacy Practice, March 1, 2001; 7(1): 9 - 25. [Abstract] [PDF]
|
|
|
|
|
|
S. Braun, G. Schlimok, I. Heumos, G. Schaller, L. Riethdorf, G. Riethmüller, and K. Pantel erbB2 Overexpression on Occult Metastatic Cells in Bone Marrow Predicts Poor Clinical Outcome of Stage I-III Breast Cancer Patients Cancer Res., March 1, 2001; 61(5): 1890 - 1895. [Abstract] [Full Text]
|
|
|
|
|
|
F. M. Sirotnak, M. F. Zakowski, V. A. Miller, H. I. Scher, and M. G. Kris Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clin. Cancer Res., December 1, 2000; 6(12): 4885 - 4892. [Abstract] [Full Text]
|
|
|
|
|
|
J. Mendelsohn Use of an Antibody to Target Geldanamycin J Natl Cancer Inst, October 4, 2000; 92(19): 1549 - 1551. [Full Text] [PDF]
|
|
|
|
|
|
R. Mandler, C. Wu, E. A. Sausville, A. J. Roettinger, D. J. Newman, D. K. Ho, C. R. King, D. Yang, M. E. Lippman, N. F. Landolfi, et al. Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines J Natl Cancer Inst, October 4, 2000; 92(19): 1573 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Krystal, S. Honsawek, J. Litz, and E. Buchdunger The Selective Tyrosine Kinase Inhibitor STI571 Inhibits Small Cell Lung Cancer Growth Clin. Cancer Res., August 1, 2000; 6(8): 3319 - 3326. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Gong, N. Nikrui, D. Chen, S. Koido, Z. Wu, Y. Tanaka, S. Cannistra, D. Avigan, and D. Kufe Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity J. Immunol., August 1, 2000; 165(3): 1705 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Strawn, F. Kabbinavar, D. P. Schwartz, E. Mann, L. K. Shawver, D. J. Slamon, and J. M. Cherrington Effects of SU101 in Combination with Cytotoxic Agents on the Growth of Subcutaneous Tumor Xenografts Clin. Cancer Res., July 1, 2000; 6(7): 2931 - 2940. [Abstract] [Full Text]
|
|
|
|
|
|
M. S. Orr, P. M. O'Connor, and K. W. Kohn Effects of c-erbB2 Overexpression on the Drug Sensitivities of Normal Human Mammary Epithelial Cells J Natl Cancer Inst, June 21, 2000; 92(12): 987 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mendelsohn Blockade of Receptors for Growth Factors: An Anticancer Therapy -- The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture Clin. Cancer Res., March 1, 2000; 6(3): 747 - 753. [Full Text]
|
|
|
|
|
|
S. Braun, C. Kentenich, W. Janni, F. Hepp, J. de Waal, F. Willgeroth, H. Sommer, and K. Pantel Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients J. Clin. Oncol., January 5, 2000; 18(1): 80 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Donato, M. Perez, H. Kang, Z. H. Siddik, Y.-H. Ling, and R. Perez-Soler EGF Receptor and p21WAF1 Expression are Reciprocally Altered as ME-180 Cervical Carcinoma Cells Progress from High to Low Cisplatin Sensitivity Clin. Cancer Res., January 1, 2000; 6(1): 193 - 202. [Abstract] [Full Text]
|
|
|
|
|
|
P. A. Trail, D. Willner, A. B. Bianchi, A. J. Henderson, M. D. TrailSmith, E. Girit, S. Lasch, I. Hellstrom, and K. E. Hellstrom Enhanced Antitumor Activity of Paclitaxel in Combination with the Anticarcinoma Immunoconjugate BR96-Doxorubicin Clin. Cancer Res., November 1, 1999; 5(11): 3632 - 3638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Agus, H. I. Scher, B. Higgins, W. D. Fox, G. Heller, M. Fazzari, C. Cordon-Cardo, and D. W. Golde Response of Prostate Cancer to Anti-Her-2/neu Antibody in Androgen-dependent and -independent Human Xenograft Models Cancer Res., October 1, 1999; 59(19): 4761 - 4764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Akimoto, N. R. Hunter, L. Buchmiller, K. Mason, K. K. Ang, and L. Milas Inverse Relationship between Epidermal Growth Factor Receptor Expression and Radiocurability of Murine Carcinomas Clin. Cancer Res., October 1, 1999; 5(10): 2884 - 2890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, et al. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease J. Clin. Oncol., September 1, 1999; 17(9): 2639 - 2639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Hengstler, J. Lange, A. Kett, N. Dornhofer, R. Meinert, M. Arand, P. G. Knapstein, R. Becker, F. Oesch, and B. Tanner Contribution of c-erbB-2 and Topoisomerase II{{alpha}} to Chemoresistance in Ovarian Cancer Cancer Res., July 1, 1999; 59(13): 3206 - 3214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Rosenblum, L. K. Shawver, J. W. Marks, J. Brink, L. Cheung, and B. Langton-Webster Recombinant Immunotoxins Directed against the c-erb-2/HER2/neu Oncogene Product: In Vitro Cytotoxicity, Pharmacokinetics, and in Vivo Efficacy Studies in Xenograft Models Clin. Cancer Res., April 1, 1999; 5(4): 865 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Pietras, J. C. Poen, D. Gallardo, P. N. Wongvipat, H. J. Lee, and D. J. Slamon Monoclonal Antibody to HER-2/neuReceptor Modulates Repair of Radiation-induced DNA Damage and Enhances Radiosensitivity of Human Breast Cancer Cells Overexpressing This Oncogene Cancer Res., March 1, 1999; 59(6): 1347 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, Y.-K. Lau, W. Xia, G. N. Hortobagyi, and M.-C. Hung Tyrosine Kinase Inhibitor Emodin Suppresses Growth of HER-2/neu-overexpressing Breast Cancer Cells in Athymic Mice and Sensitizes These Cells to the Inhibitory Effect of Paclitaxel Clin. Cancer Res., February 1, 1999; 5(2): 343 - 353. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
